BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16295464)

  • 1. Diagnosis of malignancy of prostate.
    Kapoor N; Surange S; Gupta KN; Husainy MA; Faizi M
    Indian J Pathol Microbiol; 2004 Apr; 47(2):186-8. PubMed ID: 16295464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
    Yesner R; Kelly LJ; Chan YK
    Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
    Goel T; Garg S
    Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Determination of tumor markers in the diagnosis of prostatic cancer].
    Casas Terrón E; Mari Ruiz M; Molina Andreu E
    Arch Esp Urol; 1993 Mar; 46(2):99-103. PubMed ID: 7684585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the prostate specific antigen (P.S.A.) in early detection of prostate cancer in males over the age of 50.
    Smalley DL; West SK
    J Insur Med; 1994-1995 Winter; 26(4):401-2. PubMed ID: 10151084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The diagnostic utility of PSA density].
    Alcover J; Filella J; Vendrell JR; Molina R; Ballesta AM; Carretero P
    Actas Urol Esp; 1995 Mar; 19(3):192-5. PubMed ID: 8659275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.
    Inahara M; Suzuki H; Kojima S; Komiya A; Fukasawa S; Imamoto T; Naya Y; Ichikawa T
    Urology; 2006 Oct; 68(4):815-9. PubMed ID: 17070359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate.
    Kapoor N; Jain R; Surange S; Bhardwaj VK; Srivastava A
    Indian J Pathol Microbiol; 2006 Apr; 49(2):178-81. PubMed ID: 16933710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
    Bhuiyan AK; Kibria SA; Subhan SS
    Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Elements of the early diagnosis and staging of prostatic cancer. Functional results of radical surgery. Apropos of 50 complete prostatectomies].
    Lange D; Bruce W; Grellier P
    Ann Urol (Paris); 1990; 24(2):103-8. PubMed ID: 1693480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria.
    Udeh EI; Nnabugwu II; Ozoemena FO; Ugwumba FO; Aderibigbe AS; Ohayi SR; Echetabu KN
    World J Surg Oncol; 2016 Jun; 14(1):174. PubMed ID: 27356753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early detection of prostatic carcinoma: Is PSA screening suitable?].
    Kaulen H
    Dtsch Med Wochenschr; 2003 May; 128(18):977. PubMed ID: 12755136
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
    Chung BH; Hong SJ; Cho JS; Seong DH
    BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
    Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
    Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.